Bridge–TIMI 73a Trial Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk A randomized, placebo-controlled, double-blind trial Objective:To assess the efficacy and safety of olezarsen for lowering triglyceride levels in patients with moderate hypertriglyceridemia plus elevated cardiovascular risk and in … Read More
hyperlipidemia
FCS BALANCE: Olezarsen in Familial Chylomicronemia Syndrome
FCS BALANCE Trial Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (FCS) A phase 3, double-blind, placebo-controlled trial Objective:To assess the efficacy and safety of olezarsen (given once every 4 weeks) in reducing fasting triglyceride level in patients with familial chylomicronemia … Read More
WOSCOPS Trial: Pravastatin’s Role in Reducing the Incidence of MI and Death
WOSCOPS Trial Summary “The WOSCOPS Trial: Pravastatin’s Role in Reducing the Incidence of Myocardial Infarction and Death from Cardiovascular Causes” The West of Scotland Coronary Prevention Study (WOSCOPS) has significantly contributed to our understanding of the role of pravastatin in … Read More
PROMINENT Trial: Evaluating the Efficacy of Pemafibrate in Reducing Cardiovascular Events
High levels of triglycerides, a type of fat found in the blood, have been connected to an increased risk of cardiovascular diseases. The question of whether decreasing these levels can reduce the incidence of cardiovascular events has been under investigation. … Read More
ALLHAT-LLT Trial Summary: Pravastatin in Moderate HLD
2002 ALLHAT-LLT Pravastatin vs Usual Care in Moderately Hypercholesterolemic, Hypertensive Patients Multicenter, randomized, nonblinded trial M Objective: To determine whether pravastatin compared with usual care reduces all-cause mortality in older, moderately hypercholes- terolemic, hypertensive participants with at least 1 additional … Read More
AIM-HIGH Trial: Niacin + Statins in Hyperlipidemia
2011 AIM-HIGH TRIAL Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy Placebo controlled, randomized clinical trial Σ Objective: To assess if extended-release niacin added to simvastatin to raise low levels of high-density lipoprotein (HDL) cholesterol is … Read More
ODYSSEY COMBO II Trial Summary: Alirocumab in High CV risk Patients with Hypercholesterolemia
2015 ODYSSEY COMBO II TRIAL Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia double-blind, double-dummy, placebo controlled, parallel, randomized controlled trial Objective: To assess the efficacy & safety of alirocumab compared with therapy to … Read More